![]() ![]() |
|
|
||||||||
|
ZOMETA® effectively inhibits the vicious cycle of bone destruction in patients like Anthony when given 4 mg every 3 to 4 weeks10
Change from baseline in bone resorption marker*
(after single 4-mg dose of ZOMETA; N=12)11
*Urinary N-telopeptide/creatinine ratio was chosen as the surrogate marker.
Only dosing every 3 to 4 weeks has been proven effective in reducing
|
|||||||||||||||||||||
| Page
|
|
Disclaimer: This is an international website for ZOMETA® (zoledronic acid) and is intended for healthcare professionals outside the US. If you are a US resident, please click on the US Residents link at the top of this page. The information on this site is not country-specific and may contain information that is outside the approved indications in the country in which you are located.
About ZOMETA |
ZOMETA Patient Case Studies |
ZOMETA Dosing & Administration |
ZOMETA Safety & Tolerability |
ZOMETA Clinical News |
ZOMETA For Your Patients |
Professional Resource Center |
||
|
|
||
|
||